152 related articles for article (PubMed ID: 17404028)
1. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028
[TBL] [Abstract][Full Text] [Related]
2. Proton inactivation of melanoma cells enhanced by fotemustine.
Ristić-Fira A; Korićanac L; Žakula J; Keta O; Iannolo G; Cuttone G; Petrović I
Radiat Prot Dosimetry; 2011 Feb; 143(2-4):503-7. PubMed ID: 21183545
[TBL] [Abstract][Full Text] [Related]
3. Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Ristić-Fira AM; Korićanac LB; Zakula JJ; Valastro LM; Iannolo G; Privitera G; Cuttone G; Petrović IM
J Exp Clin Cancer Res; 2009 Apr; 28(1):50. PubMed ID: 19358719
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the inhibitory effects of different radiation qualities or chemotherapeutic agents on a human melanoma cell line.
Ristić-Fira AM; Petrović IM; Korićanac LB; Valastro LM; Privitera G; Cuttone G
Phys Med; 2008 Dec; 24(4):187-95. PubMed ID: 18514560
[TBL] [Abstract][Full Text] [Related]
5. Response of a human melanoma cell line to low and high ionizing radiation.
Ristic-Fira AM; Todorovic DV; Koricanac LB; Petrovic IM; Valastro LM; Cirrone PG; Raffaele L; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():165-74. PubMed ID: 17404029
[TBL] [Abstract][Full Text] [Related]
6. Radiobiological analysis of human melanoma cells on the 62 MeV CATANA proton beam.
Petrović I; Ristić-Fira A; Todorović D; Valastro L; Cirrone P; Cuttone G
Int J Radiat Biol; 2006 Apr; 82(4):251-65. PubMed ID: 16690593
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour activity of fotemustine and protons in combination with bevacizumab.
Korićanac LB; Zakula JJ; Petrović IM; Valastro LM; Cirrone GA; Cuttone G; Ristić-Fira AM
Chemotherapy; 2010; 56(3):214-22. PubMed ID: 20551638
[TBL] [Abstract][Full Text] [Related]
8. Early effects of gamma rays and protons on human melanoma cell viability and morphology.
Todorović D; Petrović I; Todorović M; Cuttone G; Ristić-Fira A
J Microsc; 2008 Dec; 232(3):517-21. PubMed ID: 19094032
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of HTB63 human melanoma cells by irradiation with protons and gamma rays.
Ristic-Fira A; Petrovic I; Todorovic D; Koricanac L; Vujèic M; Demajo M; Sabini G; Cirrone P; Cuttone G
Oncol Rep; 2004 Dec; 12(6):1323-8. PubMed ID: 15547758
[TBL] [Abstract][Full Text] [Related]
10. Response of a radioresistant human melanoma cell line along the proton spread-out Bragg peak.
Petrović I; Ristić-Fira A; Todorović D; Korićanac L; Valastro L; Cirrone P; Cuttone G
Int J Radiat Biol; 2010 Sep; 86(9):742-51. PubMed ID: 20597839
[TBL] [Abstract][Full Text] [Related]
11. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
12. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract][Full Text] [Related]
13. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Hill HZ; Hill GJ
Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
[TBL] [Abstract][Full Text] [Related]
14. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
[TBL] [Abstract][Full Text] [Related]
15. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
16. Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice.
Thallinger C; Skorjanec S; Soleiman A; Tzaneva S; Griss J; Rous W; Poeppl W; Weinlich G; Karimian-Teherani D; Joukhadar C
Pharmacology; 2008; 82(3):233-8. PubMed ID: 18810248
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
[TBL] [Abstract][Full Text] [Related]
19. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
20. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
